{
  "drugid": "RxNorm:41127",
  "drugname": "fluvastatin",
  "guidelinename": "SLCO1B1, ABCG2, CYP2C9, and Statins",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-statins/",
  "guidelinepharmgkbids": [
    "PA166105005",
    "PA166262221",
    "PA166262241",
    "PA166262261",
    "PA166262281",
    "PA166262321",
    "PA166262341"
  ],
  "citations": [
    {
      "pmid": "22617227",
      "title": "The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy",
      "authors": [
        "Wilke R A",
        "Ramsey L B",
        "Johnson S G",
        "Maxwell W D",
        "McLeod H L",
        "Voora D",
        "Krauss R M",
        "Roden D M",
        "Feng Q",
        "Cooper-Dehoff R M",
        "Gong L",
        "Klein T E",
        "Wadelius M",
        "Niemi M"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2012
    },
    {
      "pmid": "24918167",
      "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update",
      "authors": [
        "Ramsey Laura B",
        "Johnson Samuel G",
        "Caudle Kelly E",
        "Haidar Cyrine E",
        "Voora Deepak",
        "Wilke Russell A",
        "Maxwell Whitney D",
        "McLeod Howard L",
        "Krauss Ronald M",
        "Roden Dan M",
        "Feng Qiping",
        "Cooper-DeHoff Rhonda M",
        "Gong Li",
        "Klein Teri E",
        "Wadelius Mia",
        "Niemi Mikko"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2014
    },
    {
      "pmid": "35152405",
      "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.",
      "authors": [
        "Cooper-DeHoff Rhonda M",
        "Niemi Mikko",
        "Ramsey Laura B",
        "Luzum Jasmine A",
        "Tarkiainen E Katriina",
        "Straka Robert J",
        "Gong Li",
        "Tuteja Sony",
        "Wilke Russell A",
        "Wadelius Mia",
        "Larson Eric A",
        "Roden Dan M",
        "Klein Teri E",
        "Yee Sook Wah",
        "Krauss Ronald M",
        "Turner Richard M",
        "Palaniappan Latha",
        "Gaedigk Andrea",
        "Giacomini Kathleen M",
        "Caudle Kelly E",
        "Voora Deepak"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "No Result"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "No Result"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "No Result"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "No Result"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "No Result"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "No Result"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 genotype result is not available.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "No Result"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg."
      },
      "drugrecommendation": "Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Poor Function"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Poor Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.",
        "SLCO1B1": "Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg."
      },
      "drugrecommendation": "Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer",
        "SLCO1B1": "Possible Decreased Function"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5",
        "SLCO1B1": "Possible Decreased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "No Result"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "No Result"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "No Result"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "No Result"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "Increased Function"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Increased Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal exposure.",
        "SLCO1B1": "Typical myopathy risk and statin exposure."
      },
      "drugrecommendation": "Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer",
        "SLCO1B1": "Normal Function"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0",
        "SLCO1B1": "Normal Function"
      },
      "comments": "The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "n/a",
      "classification": "n/a",
      "phenotypes": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "No Result"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "No Result",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "n/a",
      "classification": "n/a",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "Indeterminate"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a",
        "SLCO1B1": "n/a"
      },
      "drugrecommendation": "n/a",
      "classification": "n/a",
      "phenotypes": {
        "CYP2C9": "Indeterminate",
        "SLCO1B1": "No Result"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a",
        "SLCO1B1": "No Result"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2C9",
    "SLCO1B1"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.22.2",
  "source": "CPIC"
}